NewcelX (NCEL) Preferred Shares (2024 - 2025)
NewcelX (NCEL) posted quarterly Preferred Shares of $4000.0 for Q4 2025, down 53.41% year-over-year from $8586.0 in Q4 2024, and down 90.6% quarter-over-quarter from $42539.0 in Q2 2025.
NewcelX (NCEL) Preferred Shares (2024 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Preferred Shares for 2 consecutive years, with $4000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Preferred Shares fell 53.41% year-over-year to $4000.0; the TTM figure through Dec 2025 stood at $4000.0 (down 53.41% YoY), while the FY2025 annual figure was $4000.0, down 53.41% from the prior year.
- Preferred Shares fell to $4000.0 in Q4 2025 per NCEL's latest filing, from $42539.0 in the prior quarter.
- Across five years, Preferred Shares topped out at $42539.0 in Q2 2025 and bottomed at $4000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,000.00 |
| Jun 30, 2025 | 42,539.00 |
| Dec 31, 2024 | 8,586.00 |